Exelixis, Inc. - Common Stock — 현금 흐름 (NASDAQ:EXEL)

Financials

영업활동으로 인한 현금 400.8 M362.61 M333.32 M699.97 M884.27 M 924.67 M 투자 활동으로 인한 현금 -42.88 M-524.41 M-26.95 M-116.78 M350.44 M 249.61 M 재무활동으로 인한 현금 -14.8 M586 K-546.05 M-628.81 M-969.59 M -1.13 B 잉여 현금 흐름 400.8 M362.61 M333.32 M699.97 M875.84 M 917.69 M

Exelixis, Inc. - Common Stock

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

EXEL

Financials

Exelixis, Inc. - Common Stock

뉴스

Dow Jones Futures: Stock Market Hits Highs On U.S.-Iran Deal; Dell Surges On Earnings

Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Exelixis: Financial Performance Improves Faster Than Market Expectations (NASDAQ:EXEL)

Tracking Renaissance Technologies (RenTec) 13F Portfolio – Q1 2026 Update

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study

Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?

Stock Market Soars On Tumbling Oil Prices, Strong Earnings: Weekly Review

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Here's Why Exelixis (EXEL) is a Strong Value Stock

Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript